This trial is evaluating whether adapted Chicago Run running program will improve 4 primary outcomes and 2 secondary outcomes in patients with Myelocele. Measurement will happen over the course of at 8 weeks.
This trial requires 25 total participants across 2 different treatment groups
This trial involves 2 different treatments. Adapted Chicago Run Running Program is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
It is important to have a good understanding of patient characteristics, which differ depending on ethnicity. Understanding factors associated with a high likelihood of enrollment in clinical trials may inform enrollment strategies.
The risk of having myelomeningocele was markedly increased in family members of a patient with myelomeningocele. Moreover, mothers with myelomeningocele and their mothers were more likely to have another child with myelomeningocele or congenital hydrocephalus.
Current therapies are not always successful and can result in poor long-term outcomes. There is a need to study long-term quality-of-life outcomes to gain more information that can be used by doctors and patient families for more informed treatment decisions.
It is important to treat, when possible, the underlying causes. Patients with myelocele who have not received surgery may have poor overall and neurological outcomes. Long-term follow-up is essential.
The findings of the study may help to understand the pathology of myelocele. It is important to discuss the risks about the procedure before the first ultrasound examination of a child with bilateral cystic abdominal masses.
At least 200 cases of myelocele are diagnosed each year in the US. Males and females are equally affected. The incidence has increased in the last decade, as demonstrated by the increase in the number of cases of this rare defect. Therefore, prompt neonatal and pediatric care is crucial to minimize these complications.
In a recent study, findings we have demonstrated that the majority of cases are attributed to the rupture of the neural tube. The reason for this can be explained by its anatomical characteristics or the rupture can occur from an indirect injury such as trauma.
A survey of family information about skeletal abnormalities in infants with a congenital muscular anomaly has the potential to identify all potentially relevant cases, and to help in deciding whether more detailed investigations are warranted, and in choosing the optimum age to collect family history information.
This retrospective study suggests that children with CCM may have improved motor function, lower spasticity, and lower passive stiffness when taking part in the AT programme.
There is little evidence that a combined exercise program would have any beneficial effect on any of the health care indicators in our study cohort.
Although no new studies were published on myelocele treatment, [a 2017 review article in JAMA Pediatrics by P.L. Clark et al. illustrates how] patients with myelocele who are treated at the Children's Hospital of Philadelphia have the best chance for survival. [A 2016 study by G.B. Clark et al. found that] most patients with myelocele die before they reach 8 years of age and that [all three deaths occurred] before they had reached 25 years of age. [Another 2016 study by P.J. Parnia et al. found that] 80% of patients with myelocele do not survive into their early teens.] A myelocele can be a tragic event.
Adapted CH ran is safe and feasible in mild to moderate cases. More cases could be treated with a more intense program and modified exercise regimen. However, we do not recommend adapted CH ran for severe cases.